Clinical Trials · NCT06109311
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 546
- Start date
- Nov 2023
- Locations
- 70 sites, 6 countries
- Primary endpoint
- Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)